(2S,4S)-tert-butyl 4-amino-2-((tert-butyl-dimethylsilyloxy)methyl)pyrrolidine-1-carboxylate | 348165-58-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2S,4S)-tert-butyl 4-amino-2-((tert-butyl-dimethylsilyloxy)methyl)pyrrolidine-1-carboxylate
• 英文别名: (2S,4S)-4-amino-2-(tert-butyldimethylsilanyloxymethyl)pyrrolidine-1-carboxylic acid tert-butyl ester；N-Boc-4S-amino-2S-O-TBS-prolinol；tert-Butyl (2S,4S)-4-amino-2-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidine-1-carboxylate；tert-butyl (2S,4S)-4-amino-2-[[tert-butyl(dimethyl)silyl]oxymethyl]pyrrolidine-1-carboxylate
• CAS: 348165-58-2
• 化学式: C₁₆H₃₄N₂O₃Si
• 分子量: 330.543
• InChiKey: NVCPPDYIQGPXBI-STQMWFEESA-N

物化性质

• 沸点：
  365.5±27.0 °C(Predicted)
• 密度：
  0.981±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.34
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  64.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2S,4S)-tert-butyl 4-amino-2-((tert-butyl-dimethylsilyloxy)methyl)pyrrolidine-1-carboxylate 在 吡啶 、 sodium azide 、 palladium 10% on activated carbon 、 四丁基氟化铵 、 氢气 、 碳酸氢钠 、 potassium carbonate 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 60.0 ℃ 、275.8 kPa 条件下， 反应 28.5h， 生成 ethyl [N-(N-Boc-pyrrolidin-3-yl-2S-Fmoc-aminomethyl)-N-(N₁-thyminylacetyl)]glycine
  参考文献：
  名称：

  C3′-endo-puckered pyrrolidine containing PNA has favorable geometry for RNA binding: Novel ethano locked PNA (ethano-PNA)

  摘要：

  A novel peptide nucleic acid (PNA) analogue is designed with a constraint in the aminoethyl segment of the aegPNA backbone so that the dihedral angle beta is restricted within 60-80 degrees, compatible to form PNA:RNA duplexes. The designed monomer is further functionalized with positively charged amino-/guanidino-groups. The appropriately protected monomers were synthesized and incorporated into aegPNA oligomers at predetermined positions and their binding abilities with cDNA and RNA were investigated. A single incorporation of the modified PNA monomer into a 12-mer PNA sequence resulted in stronger binding with complementary RNA over cDNA. No significant changes in the CD signatures of the derived duplexes of modified PNA with complementary RNA were observed. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.015
• 作为产物：
  描述：

  反式-4-羟基-L-脯氨酸甲酯 在 吡啶 、 咪唑 、 sodium tetrahydroborate 、 sodium azide 、 palladium 10% on activated carbon 、 氢气 、 三乙胺 、 lithium chloride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 60.0 ℃ 、275.8 kPa 条件下， 反应 37.75h， 生成 (2S,4S)-tert-butyl 4-amino-2-((tert-butyl-dimethylsilyloxy)methyl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  C3′-endo-puckered pyrrolidine containing PNA has favorable geometry for RNA binding: Novel ethano locked PNA (ethano-PNA)

  摘要：

  A novel peptide nucleic acid (PNA) analogue is designed with a constraint in the aminoethyl segment of the aegPNA backbone so that the dihedral angle beta is restricted within 60-80 degrees, compatible to form PNA:RNA duplexes. The designed monomer is further functionalized with positively charged amino-/guanidino-groups. The appropriately protected monomers were synthesized and incorporated into aegPNA oligomers at predetermined positions and their binding abilities with cDNA and RNA were investigated. A single incorporation of the modified PNA monomer into a 12-mer PNA sequence resulted in stronger binding with complementary RNA over cDNA. No significant changes in the CD signatures of the derived duplexes of modified PNA with complementary RNA were observed. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.015

文献信息

• [EN] PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE<br/>[FR] PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINES EN TANT QU'INHIBITEURS DE CDK ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：CANCER REC TECH LTD

  公开号：WO2015124941A1

  公开（公告）日：2015-08-27

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyrazolo[1,5-a]pyrimidine-5,7- diamine compounds (referred to herein as "PPDA compounds") that, inter alia, inhibit (e.g., selectively inhibit) CDK (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK; and to treat disorders including: disorders that are associated with CDK; disorders that result from an inappropriate activity of a cyclin-dependent kinase (CDK); disorders that are associated with CDK mutation; disorders that are associated with CDK overexpression; disorders that are associated with upstream pathway activation of CDK; disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; and cardiovascular disorders (including atherosclerosis). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些吡唑并[1,5-a]嘧啶-5,7-二胺化合物（以下简称为“PPDA化合物”），其在一定程度上抑制（例如，选择性抑制）CDK（例如CDK1、CDK2、CDK4、CDK5、CDK6、CDK7、CDK8、CDK9、CDK10、CDK11、CDK12、CDK13等）。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物和组合物，无论是体外还是体内，来抑制CDK；并用于治疗包括：与CDK相关的疾病；由于细胞周期依赖性激酶（CDK）不适当活性而导致的疾病；与CDK突变相关的疾病；与CDK过表达相关的疾病；与上游通路激活CDK相关的疾病；通过抑制CDK改善的疾病；增生性疾病；癌症；病毒感染（包括HIV）；神经退行性疾病（包括阿尔茨海默病和帕金森病）；缺血；肾脏疾病；和心血管疾病（包括动脉粥样硬化）等疾病。可选地，治疗还进一步包括与另一活性药剂（例如芳香化酶抑制剂、抗雌激素、Her2阻断剂、细胞毒性化疗药物等）一起进行治疗（例如同时或顺序治疗）。
• EP3321256
  申请人：——

  公开号：——

  公开（公告）日：——